The study was conducted at the CCTSI's Clinical Translational Research Center.
CU Anschutz
Anschutz Health Sciences Building
1890 N Revere Ct
Campus Box B141
Aurora, CO 80045
The study was conducted at the CCTSI's Clinical Translational Research Center.
CCTSI's pilot awardee's project helps launch Denver program that links care, services and housing.
The Conversation US asked Dr. Jacob Pellinen, a neurologist specializing in epilepsy, to walk us through how to recognize a seizure in a bystander or loved one and what to do in those crucial moments after a seizure begins. Research is supported by the Colorado Clinical and Translational Sciences Institute.
Chris DeSouza, who leads the Clinical Translational Research Center at CU Boulder, said the center is the only one housed in an undergraduate non-medical campus nationwide. It’s supporting more than a dozen active research protocols at CU Boulder.
Leaders of CCTSI on how $54 million grant will help power innovation, health equity.
The funding, to be awarded over a seven-year period, is the fourth consecutive time the federal agency has funded the Colorado Clinical and Translational Sciences Institute located on the CU Anschutz campus in Aurora since 2008.
The outpatient clinics of the Colorado Clinical and Translational Sciences Institute (CCTSI) on the CU Anschutz campus was one of the sites where researchers worked.
The studies, which are part of the RECOVER initiative, target a host of symptoms that are most troubling for patients enduring long-term health effects after COVID-19.
“I am absolutely thrilled to have Mayor Coleman and Dr. Nease joining us as trustees,” said the Rev. Louise Westfall, 2023 board chair of The Colorado Trust.
"We are really struggling with maintaining effective therapeutic options for high-risk patients with COVID-19," said Dr. Adit Ginde.
CCTSI Community Research Liaison gathers 80 San Louis Valley organizations to help fight scarcity of childcare.
The Colorado Clinical and Translational Sciences Institute has been putting a focus on recruiting diverse participants in clinical research—the OARS program is key to this effort.
Melissa Haendel’s background in genetic research might be the key to coordinating rare disease information across the CU Anschutz Campus—and the world. Haendel is one of the leaders in the Colorado Clinical and Translational Sciences Institute (CCTSI).
A CCTSI study looking at the long-term side effects some patients are facing months after a positive COVID-19 test, a condition often called long COVID, is searching for more participants.
In our new series Beyond the Scale, NBC’s John Torres reports for TODAY on a groundbreaking study at the National Institutes of Health that could help doctors prescribe personalized workout plans for patients.
Even two years after their initial infection, the majority of people who were hospitalized with Covid-19 early in the pandemic had lingering symptoms, according to a new study that may be one of the longest and largest on record to follow people with long Covid.
Carey Candrian, a member of the CCTSI PACT Council, received multiple grants to work on the project titled Eye to Eye, which is on display at the Fulginiti Pavilion for Bioethics and Humanities on the CU Anschutz campus.
Long Covid, with its constellation of symptoms, is proving a challenging moving target for researchers trying to conduct large studies of the syndrome. As they take aim, they’re debating how to responsibly use growing piles of real-world data — drawing from the full experiences of long Covid patients, not just their participation in stewarded clinical trials.
A collaboration between the CU Cancer Center, the Anschutz Health and Wellness Center, the Colorado NORC, and the Colorado Clinical and Translational Sciences Institute, the study will look not just at how losing weight might help breast cancer survivors prevent relapse, but if certain dietary weight-loss strategies have additional benefits when it comes to the disease.
This type of treatment is part of the latest push from the state to keep COVID-19 patients out of the hospital.
An elementary school boy came to every appointment in a kid-sized lab coat, a children’s book about mRNA vaccines in his arms. Another child announced she was “helping science.” And Kaniya Smith told her friends in the fourth grade that she was taking the coronavirus vaccine to test it out for the rest of them.
Phil Zeitler, MD, Ph.D., has been treating youth with type 2 diabetes for more than 20 years. He and a team of researchers published a paper today on the TODAY2 study in the New England Journal of Medicine on the long-term complications of type 2 diabetes. (TODAY stands for Treatment Options for type 2 Diabetes in Adolescents and Youth. The first phase of the study took place from 2004—2011; phase two from 2011—2020. Both studies involved more than 550 participants from across the country.)
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children’s Hospital Colorado and published May 6, 2021, in Lancet Respiratory Medicine shows that the CFTR modulator – lumacaftor/ivacaftor – can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.
DENVER (KDVR) — As many focus on the race to get Coloradans vaccinated against COVID-19, doctors and scientists continue to work to improve treatments for those who contract the virus. Monoclonal Antibody treatment first gained attention last fall as the U.S. Food and Drug Administration issued emergency use authorization to use it to treat mild to moderate cases of COVID-19 in adults. The treatment is more widely available now, according to Dr. Adit Ginde, a University of Colorado School of Medicine faculty member.
1890 N Revere Ct
Campus Box B141
Aurora, CO 80045
303-724-1222
University of Colorado Anschutz Medical Campus
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.